---
title: "Zhejiang Haisen Pharmaceutical Co., Ltd. (001367.SZ)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/001367.SZ.md"
symbol: "001367.SZ"
name: "Zhejiang Haisen Pharmaceutical Co., Ltd."
industry: "Pharmaceuticals"
datetime: "2026-05-20T04:26:55.359Z"
locales:
  - [en](https://longbridge.com/en/quote/001367.SZ.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/001367.SZ.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/001367.SZ.md)
---

# Zhejiang Haisen Pharmaceutical Co., Ltd. (001367.SZ)

## Company Overview

Zhejiang Haisen Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical intermediates, active pharmaceutical ingredients, and preparations in China and internationally. The company offers active pharmaceutical ingredients for use as antilipemic agents, antipyretic analgesics, antidepressants, analgesics, antibacterial agents, histamine drugs, and anticonvulsants, as well as for anti-gastric ulcers, and digestive and cardiovascular applications. It also provides chemical products for use as paroxetine HCl and amikacin sulphate intermediates and food additives; and escitalopram oxalate tablets to treat depression and panic disorders under the Tezi brand. In addition, the company engages in the import and export of goods; trading; and medical research and experimental development activities.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | CN Market |
| Website | [www.haisenpharma.com](https://www.haisenpharma.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:10.000Z

**Overall: B (0.34)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 60 / 215 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 9.87% |  |
| Net Profit YoY | 10.96% |  |
| P/B Ratio | 2.33 |  |
| Dividend Ratio | 0.99% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 3550959396.23 |  |
| Revenue | 520476365.09 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 9.19% | B |
| Profit Margin | 25.64% | A |
| Gross Margin | 48.19% | B |
| Revenue YoY | 9.87% | B |
| Net Profit YoY | 10.96% | C |
| Total Assets YoY | 8.41% | B |
| Net Assets YoY | 10.53% | B |
| Cash Flow Margin | 122.24% | B |
| OCF YoY | 9.87% | B |
| Turnover | 0.33 | D |
| Gearing Ratio | 6.54% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Zhejiang Haisen Pharmaceutical Co., Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "9.87%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "10.96%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "2.33",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.99%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "3550959396.23",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "520476365.09",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "9.19%",
          "rating": "B"
        },
        {
          "name": "Profit Margin",
          "value": "25.64%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "48.19%",
          "rating": "B"
        },
        {
          "name": "Revenue YoY",
          "value": "9.87%",
          "rating": "B"
        },
        {
          "name": "Net Profit YoY",
          "value": "10.96%",
          "rating": "C"
        },
        {
          "name": "Total Assets YoY",
          "value": "8.41%",
          "rating": "B"
        },
        {
          "name": "Net Assets YoY",
          "value": "10.53%",
          "rating": "B"
        },
        {
          "name": "Cash Flow Margin",
          "value": "122.24%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "9.87%",
          "rating": "B"
        },
        {
          "name": "Turnover",
          "value": "0.33",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "6.54%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 26.50 | 63/215 | 29.92 | 28.98 | 27.51 |
| PB | 2.32 | 108/215 | 2.64 | 2.54 | 2.40 |
| PS (TTM) | 6.79 | 155/215 | 7.50 | 7.15 | 6.85 |
| Dividend Yield | 0.99% | 100/215 | 0.52% | 0.48% | 0.46% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Allist (688578.SH) | A | A | B | A | B | A |
| 02 | Xingqi Pharmaceutical (300573.SZ) | A | A | A | A | B | A |
| 03 | Hengrui Pharma (600276.SH) | A | B | C | A | B | B |
| 04 | Yunnan Baiyao (000538.SZ) | B | C | B | B | C | B |
| 05 | Haisco (002653.SZ) | A | A | B | B | B | B |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/001367.SZ/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/001367.SZ/norm.md)
- [Related News](https://longbridge.com/en/quote/001367.SZ/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/001367.SZ/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**